Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

Ovarian cancer is the seventh most common cancer worldwide for females and the most lethal of all gynecological malignancies. The treatment of ovarian cancer remains a challenge in spite of advances in debulking surgery and changes in both chemotherapy schedules and routes of administration. Cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanjirband, Maryam, Curtin, Nicola, Edmondson, Richard J., Lunec, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642516/
https://www.ncbi.nlm.nih.gov/pubmed/29050241
http://dx.doi.org/10.18632/oncotarget.19266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642516/
https://www.ncbi.nlm.nih.gov/pubmed/29050241
http://dx.doi.org/10.18632/oncotarget.19266

Ejemplares similares